ClinicalTrials.gov
ClinicalTrials.gov Menu

Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00823602
Recruitment Status : Unknown
Verified January 2009 by Yazd Research & Clinical Center for Infertility.
Recruitment status was:  Recruiting
First Posted : January 15, 2009
Last Update Posted : January 15, 2009
Sponsor:
Information provided by:
Yazd Research & Clinical Center for Infertility

Brief Summary:

Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.

This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.

The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .


Condition or disease Intervention/treatment Phase
Infertility Drug: ganirelix Drug: suprefact Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART
Study Start Date : March 2008
Actual Primary Completion Date : October 2008
Estimated Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: 1
GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation
Drug: ganirelix
These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).

Active Comparator: 2
GnRH agonist, suprefact, stimulation with a standard long protocol
Drug: suprefact
GnRH agonist, standard protocol




Primary Outcome Measures :
  1. pregnancy rate [ Time Frame: 2weeks ]

Secondary Outcome Measures :
  1. ovarian stimulation [ Time Frame: 10days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 35 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • first cycle of ART
  • age < 35 years
  • basal FSH < 10 IU/L

Exclusion Criteria:

  • previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine abnormality, severe endometriosis
  • only one ovary

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00823602


Contacts
Contact: razieh firouzabadi, MD 8247085 ext +98351 dr_firouzabadi@yahoo.com
Contact: shahnaz Ahmadi, MD 9173717981 ext +98 AHMADISHAHNAZ2005@yahoo.com

Locations
Iran, Islamic Republic of
Yazd Research and Clinical Center For Infertility Recruiting
Yazd, Iran, Islamic Republic of
Contact: razieh firouzabadi, MD    8247085 ext +98351    dr_firouzabadi@yahoo.com   
Contact: shahnaz Ahmadi, MD    9173717981 ext +98    AHMADISHAHNAZ2005@yahoo.com   
Principal Investigator: shahnaz ahmadi, MD         
Sponsors and Collaborators
Yazd Research & Clinical Center for Infertility
Investigators
Study Chair: razieh firouzabadi, MD Yazd Research & Clinical Center for Infertility

Responsible Party: Razieh Dehghani Firouzabadi, Yazd Research & Clinical Center for Infertility
ClinicalTrials.gov Identifier: NCT00823602     History of Changes
Other Study ID Numbers: 1387YAZDRCCI
First Posted: January 15, 2009    Key Record Dates
Last Update Posted: January 15, 2009
Last Verified: January 2009

Keywords provided by Yazd Research & Clinical Center for Infertility:
GnRH antagonist
GnRH agonist
pregnancy rate
Ovarian stimulation

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Deslorelin
Triptorelin Pamoate
Buserelin
Ganirelix
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Fertility Agents, Female
Fertility Agents